Allakos Inc. (ALLK)
Largest Insider Buys in Sector
ALLK Stock Price History Chart
ALLK Stock Performance
About Allakos Inc.
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab …
Insider Activity of Allakos Inc.
Over the last 12 months, insiders at Allakos Inc. have bought $0 and sold $87,935 worth of Allakos Inc. stock.
On average, over the past 5 years, insiders at Allakos Inc. have bought $0 and sold $142.03M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 222,222 shares for transaction amount of $4M was made by MCKEARN JOHN P () on 2018‑07‑23.
List of Insider Buy and Sell Transactions, Allakos Inc.
| 2024-06-28 | Sale | Chief Financial Officer | 87,064 0.0937% | $1.01 | $87,935 | 0.00% | ||
| 2021-09-28 | Sale | director | 4,000 0.0075% | $108.12 | $432,480 | -94.75% | ||
| 2021-06-14 | Sale | President and COO | 20,000 0.0376% | $91.62 | $1.83M | -15.78% | ||
| 2021-06-07 | Sale | President and COO | 2,487 0.0047% | $92.03 | $228,879 | -14.19% | ||
| 2021-06-04 | Sale | Chief Executive Officer | 23,595 0.044% | $89.64 | $2.11M | -12.39% | ||
| 2021-06-04 | Sale | President and COO | 642 0.0012% | $90.26 | $57,947 | -12.39% | ||
| 2021-06-04 | Sale | Chief Medical Officer | 2,435 0.0045% | $89.60 | $218,176 | -12.39% | ||
| 2021-06-03 | Sale | Chief Executive Officer | 20,001 0.0378% | $92.13 | $1.84M | -13.45% | ||
| 2021-06-02 | Sale | Chief Executive Officer | 20,001 0.0369% | $94.55 | $1.89M | -17.34% | ||
| 2021-05-19 | Sale | Chief Executive Officer | 19,998 0.0374% | $98.93 | $1.98M | -18.90% | ||
| 2021-05-18 | Sale | Chief Executive Officer | 20,001 0.0377% | $102.31 | $2.05M | -20.84% | ||
| 2021-05-17 | Sale | Chief Executive Officer | 20,001 0.0369% | $99.68 | $1.99M | -20.43% | ||
| 2021-05-10 | Sale | President and COO | 20,000 0.0377% | $96.02 | $1.92M | -14.94% | ||
| 2021-04-14 | Sale | President, COO and CFO | 20,000 0.0373% | $107.77 | $2.16M | -23.40% | ||
| 2021-04-13 | Sale | President, COO and CFO | 20,000 0.0368% | $103.08 | $2.06M | -21.06% | ||
| 2021-04-12 | Sale | President, COO and CFO | 20,000 0.0373% | $104.40 | $2.09M | -20.99% | ||
| 2021-04-06 | Sale | Chief Medical Officer | 10,000 0.0189% | $111.68 | $1.12M | -24.45% | ||
| 2021-04-05 | Sale | Chief Medical Officer | 20,000 0.0374% | $113.06 | $2.26M | -26.01% | ||
| 2021-04-01 | Sale | Chief Medical Officer | 20,000 0.0374% | $114.40 | $2.29M | -26.91% | ||
| 2021-03-26 | Sale | 17,308 0.0325% | $115.17 | $1.99M | -26.70% |
Insider Historical Profitability
| Alta Partners VIII, L.P. | 10 percent owner | 11519200 12.8931% | $0.89 | 1 | 0 | +13.36% |
| RiverVest Venture Fund III, L.P. | 10 percent owner | 5750506 6.4364% | $0.89 | 1 | 14 | +13.36% |
| JANNEY DANIEL | 56293 0.063% | $0.89 | 1 | 6 | +13.36% | |
| MCKEARN JOHN P | director | 1200 0.0013% | $0.89 | 1 | 15 | +13.36% |
Institutional Investor Ownership
| Bvf Inc Il | $20.86M | 18.69 | 16.55M | +93.54% | +$10.08M | 0.15 | |
| Nea Management Company Llc | $7.75M | 6.94 | 6.15M | 0% | +$0 | 0.04 | |
| Deep Track Capital Lp | $6.3M | 5.65 | 5M | +99.14% | +$3.14M | 0.03 | |
| BlackRock | $5.95M | 5.33 | 4.72M | -7.73% | -$498,099.38 | <0.0001 | |
| The Vanguard Group | $4.78M | 4.29 | 3.79M | +16.56% | +$679,249.54 | <0.0001 |